Clinical utility of self-assembling peptide haemostat (PuraBond®) in ENT surgery: a 600-patient observational registry at University Hospitals Birmingham.

OBJECTIVES

This study aimed to evaluate the clinical applications, observed haemostatic outcomes of a self-assembling peptide haemostat (PuraBond®) across a range of ENT surgical procedures using a large UK observational registry.

METHODS

A two-cycle observational study of 600 patients at University Hospitals Birmingham NHS Foundation Trust (September 2019-July 2024). Data collected included patient demographics, comorbidities, anticoagulation status, surgical details, intra-operative haemostatic outcomes and post-operative complications.

RESULTS

Intra-operative haemostasis was documented without the need for additional haemostatic intervention in 99.8% of cases (599/600). Immediate haemostasis-related complication rate was 0.2% (1/600). The overall complication rate was 3% per cent, with most complications unrelated to haemostasis or the use of PuraBond. The study limitations include participant heterogeneity, absence of a control group and small subspeciality sample sizes underscoring the need for comparative studies.

CONCLUSION

This registry demonstrates PuraBond's broad applicability in ENT surgery as an adjunct to routine haemostats and provides essential groundwork for designing future comparative trials.